Latest Research And Development News

Aurora Labs has landed a $1 million Australian Government grant, matched dollar-for-dollar, to boost production of its micro gas turbine propulsion systems for defence applications using commercial 3D printing technology.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

TradeWindow reported a 20% rise in FY26 revenue to NZ$9.6 million with annual recurring revenue surpassing NZ$10 million. The company narrowed its EBITDA loss and is targeting breakeven in FY27 while advancing its AI-driven FreightAI platform.

Pure Resources (ASX: PR1) has closed a $3 million placement, issuing 12 million shares after shareholder approval, while also issuing options and advisory shares to support exploration and cutting-edge carbon nanotube fibre research.

Phoslock Environmental Technologies reported a sales recovery in 2025 with further growth expected, backed by resumed production in China and promising European projects, while ongoing litigation clouds the outlook.

Ainsworth Game Technology posted a 10% revenue increase in FY25 to $291 million, driven by strong Asia Pacific growth, while North American challenges weigh on H1 2026 outlook.

CleanSpace Holdings expects modest revenue growth for FY26, hindered by product certification delays and global market challenges, while maintaining a strong cash position and preparing a new respirator launch.

Fisher & Paykel Healthcare posted a 14% revenue increase to NZ$2.31 billion and a 24% rise in net profit to NZ$468.5 million for FY2026, driven by strong hospital product sales and ongoing innovation.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Strategic Elements Limited is raising up to $1 million via a Share Purchase Plan (SPP) at 3.5 cents per share, with attaching options exercisable at 4 cents, to fuel development in Energy Ink™ and Stealth Technologies.

Island Pharmaceuticals has appointed Mark Herzog as Senior Global Health Security Advisor and secured roles in key Medical Countermeasures Coalition groups, boosting its US biodefence engagement ahead of pivotal Galidesivir Animal Rule studies.